Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Embla Medical hf. (OSSUY)
Reykjavik, IS
Embla Medical hf is an international enterprise focused on orthopedics, dedicated to the innovation, enhancement, production, and worldwide distribution of non-surgical orthopedic solutions. Its business activities are organized across various geographical divisions, including the Americas, the Europe, Middle East, and Africa (EMEA) region, and a unified segment encompassing both the Americas and Asia-Pacific. The company was established in 1971 by Össur Kristinsson and has its primary corporate office situated in Reykjavík, Iceland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -0.13% | -0.13% | -14.46% | -25.92% | -29.22% | -4.63% | -14.27% | +220.59% | -17.96% | -17.96% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Devices: +11.2%+9.1% Q1'26: +14.6% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%+25.0% Q1'26: +21.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+11.6% Q1'26: +1.7% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+13.2% ★ Q1'26: +10.3% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+6.4% ★ Q1'26: +5.3% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.1% Q1'26: -2.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×3.78× Q1'26: 3.48× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. |
Dec 2027 5 Rev. Ana. |
|---|---|---|---|---|
| Revenue |
854.89M
est: 858.49M (-0.4%)
|
932.24M
est: 926.80M (+0.6%)
|
1.02B
1.01B – 1.03B
+10.3% YoY
|
1.11B
1.10B – 1.11B
+8.1% YoY
|
| EBITDA |
167.94M
est: 163.06M (+3.0%)
|
183.71M
est: 176.03M (+4.4%)
|
194.21M
192.41M – 195.39M
+10.3% YoY
|
209.90M
208.55M – 211.21M
+8.1% YoY
|
| EBIT |
111.97M
est: 105.60M (+6.0%)
|
122.86M
est: 114.00M (+7.8%)
|
125.77M
124.60M – 126.53M
+10.3% YoY
|
135.93M
135.06M – 136.78M
+8.1% YoY
|
| Net Income |
68.28M
|
83.65M
|
—
— – —
|
—
— – —
|
| SGA |
352.15M
est: 354.58M (-0.7%)
|
377.51M
est: 382.79M (-1.4%)
|
422.32M
418.39M – 424.88M
+10.3% YoY
|
456.43M
453.50M – 459.28M
+8.1% YoY
|
| EPS |
0.16
|
0.20
|
—
— – —
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | B+ | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 3/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sveinn Solvason | President & Chief Executive Officer | 1M | male |
| Olafur Gylfason | Executive Vice President of Chronic Solutions | 539.0K | male |
| Margret Lara Fridriksdottir | Executive Vice President of People, Strategy & Sustainability | 237.0K | female |
| Ossur Kristinsson | Founder | 25.0K | male |
| Klaus Sindahl | Head of Investor Relations | — | male |
| Andre Rocha | Executive Vice President of Research & Development | — | male |
| Lukas Marklin | Chief Operating Officer | — | male |
| Christian Robinson | President Americas & Global Bracing | — | male |
| Edda H. Geirsdottir | Vice President of Corporate Communications | — | — |
| Gudny Arna Sveinsdottir | Chief Financial Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OSSUY
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
